Alirocumab therapy effectively suppresses colorectal cancer cell growth and invasion in nude mouse liver – PCSK9 is a key driver of PI3K/Akt/p-Bad-mediated cell proliferation and antiapoptotic signaling
Alirocumab-facilitated 5-FU therapy effectively suppresses PCSK9-promoted CRC proliferation/growth/invasion, highlighting that alirocumab therapy may be an alternative choice of adjuvant therapy in combination with surgery or chemotherapy.
Authors
- Jui‐Ning Yeh
- Sheung‐Fat Ko (ORCID: https://orcid.org/0000-0002-9524-6999)
- Hong‐Hwa Chen (ORCID: https://orcid.org/0000-0002-1436-6770)
- Hon-Kan Yip
- Pei‐Lin Shao (ORCID: https://orcid.org/0000-0001-6920-0447)
- Xianwu Lan
- Chi‐Ruei Huang (ORCID: https://orcid.org/0000-0001-9646-8852)
- Yi‐Ting Wang (ORCID: https://orcid.org/0000-0003-2008-4435)
- Yi-Ling Chen
- Jun Guo
Institutions
- Asia University (TW)
- Chang Gung University (TW)
- China Medical University (TW)
- Kaohsiung Chang Gung Memorial Hospital (TW)
- China Medical University Hospital (TW)
- First Affiliated Hospital of Jinan University (CN)
Publication Details
- Journal
- International Journal of Surgery
- Published
- 2025-11-10
- DOI
- https://doi.org/10.1097/js9.0000000000003728
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00